Weekly Recap: Tegoprubart 24—month kidney benefit and FDA fast—track, +13%

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) saw shares surge after the FDA granted fast-track status to tegoprubart following Phase 2 results showing significantly better kidney function through 24 months versus tacrolimus and no post—6—month rejections in the tegoprubart arm.Previous Week RecapThis…